Introduction {#s1}
============

Malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young adults aged 15--39 and the most common cancer occurring among 15--19 year olds ([@B1]). Due to the diffuse infiltration into the brain by various brain cancer types, such as glioma (i.e., astrocytoma and oligodendroglioma; WHO grade I--IV), surgical intervention is difficult and often limited ([@B2]). Consequently, there is an urgent need to understand tumor biology and subsequently identify new drug targets for the treatment of brain tumors.

Possible new drug candidates might be found in the group of neuropeptides. Neuropeptide expression has been shown in many different cancer types, and neuropeptide expression levels correlate with tumor differentiation or aggressive behavior. Thus, neuropeptides could be useful for tumor imaging and as biomarkers for prognosis. More importantly, neuropeptides are involved in tumor cell growth, invasion, and migration ([@B3]--[@B5]), supporting their potential in developing novel anti-tumor treatment strategies.

Human galanin (GAL) is a 30-aa regulatory neuropeptide which plays a role in several physiological processes. Its functions are mediated by the G protein-coupled receptors GAL~1~-R, GAL~2~-R, and GAL~3~-R that differ in their signal transduction pathways. GAL~1~-R and GAL~3~-R predominantly couple to Gi/o, leading to a reduction of cAMP and consequently an inactivation of the protein kinase A (PKA). GAL~2~-R signals via multiple classes of G proteins, but preferably via Gq/11, which results in the activation of the protein kinase C (PKC). GALRs show sequence homologies, particularly in the transmembrane regions. GAL~1~-R and GAL~3~-R show 33% sequence homology, whereas GAL~2~-R and GAL~3~-R show 54% sequence homology ([@B6]). Besides species-specific expression patterns of GAL and galanin receptors (GALRs), expression is also tissue-specific. GAL is expressed in neuronal and endocrinal tissues at highest levels. In addition, GALRs are expressed in different tissues, with GAL~1~-R mRNA in particular being strongly expressed in the brain. GAL~2~-R mRNA is less abundant and restricted to certain brain regions, whereas GAL~3~-R mRNA is more restricted to peripheral tissues ([@B6]). Recently, expression of GAL and GALRs in human immune cells such as neutrophils and macrophages was also reported ([@B7]).

Human pheochromocytoma was the first tumor in which GAL was identified ([@B8], [@B9]). Later, GAL-like immunoreactivity was detected in other neuroendocrine tumors, including human pituitary adenoma, particularly associated with adrenocorticotrophic hormone-secreting cells ([@B10]--[@B16]), and gangliocytoma ([@B14], [@B17]), paraganglioma ([@B18], [@B19]), and neuroblastoma ([@B20]). GAL has also been detected in a variety of non-neuroendocrine human tumors of different origin, including glioblastoma and other brain tumors ([@B21]), melanoma ([@B22]), head and neck squamous cell carcinoma (HNSCC) ([@B23]), basal cell carcinoma ([@B24]), colon cancer ([@B25]--[@B27]) and embryonic carcinoma ([@B28]). Interestingly, the majority of these tumors exhibited significantly higher GAL levels than corresponding non-cancerous tissue ([@B22], [@B23], [@B25], [@B27], [@B28]). In colon cancers, GAL mRNA levels correlated with tumor size and stage ([@B25]), for which a significant correlation between high GAL expression and shorter disease-free survival in colon cancer patients was observed ([@B27]).

In humans, GALRs were first discovered in pituitary tumors ([@B29]) and subsequently identified in pheochromocytoma ([@B30]), neuroblastoma ([@B20]), glioma ([@B21]), prostate carcinoma ([@B30]), colon carcinoma ([@B27]), and HNSCC ([@B31]). GAL~1~-R mRNA is the most abundantly expressed GALR mRNA in human meningioma, glioblastoma ([@B21]) and neuroblastoma ([@B32]). Elevated GAL~1~-R mRNA expression is associated with increased malignancy ([@B33]). Increased GAL~1~-R mRNA expression was also observed in human pituitary adenoma relative to levels in normal human pituitary gland ([@B34]), suggesting cancer-promoting properties for GAL~1~-R at least in these tumors. Furthermore, activation of GAL~1~-R induces cell-cycle arrest and suppresses proliferation of HNSCC cell lines ([@B31], [@B35], [@B36]). Anti-proliferative effects via GAL~1~-R signaling have also been observed in human SH-SY5Y neuroblastoma cells transfected with GAL~1~-R ([@B37]).

In contrast, the presence of GAL~2~-R mRNA is less common in human glioma ([@B21]) and neuroblastoma ([@B20]). GAL~2~-R mRNA expression is low in the majority of human pituitary adenomas compared to levels in normal human pituitary ([@B34]). However, elevated GAL~2~-R mRNA expression was observed in human pheochromocytoma ([@B38]).

It is noteworthy that transfection of GAL~2~-R into human SH-SY5Y neuroblastoma cells and into human HNSCC cells led to suppressed cell proliferation and induction of caspase-dependent apoptosis ([@B36]--[@B40]). On the other hand, in small cell lung cancer, activation of GAL~2~-R exerted growth-promoting effects ([@B41], [@B42]).

The impact of GAL~3~-R signaling on the biological activity of cancer cells is less well-studied. GAL~3~-R expression was detected in neuroblastoma ([@B32], [@B33]) and glioma ([@B21]). Analysis of human HNSCC revealed significantly increased GAL~3~-R expression in the tumors compared to normal tissue ([@B23]). Similarly, GAL~3~-R mRNA expression was detected in human pituitary adenoma associated with tumor relapse, whereas it was absent in post-mortem pituitary glands ([@B34]).

To date, GAL-binding studies have been used to deduce the presence of GALRs in human glioma, meningioma ([@B21]) and pituitary adenoma ([@B29]), but no receptor subtype has been identified at the cellular level, except indirectly from mRNA expression analyses in tissue extracts ([@B21], [@B34]). Thus, information on the cellular distribution of GALRs has been missing due to a lack of specific GAL receptor antibodies. Recently, we were able to identify specific anti-human GALR- specific antibodies, which now allow us to determine the distribution of the three GALRs at the cellular level ([@B43]).

The aim of the present study was to elucidate the expression of GAL and GALRs in different human brain tumors by immunohistochemistry (IHC) with carefully validated antibodies.

Materials and Methods {#s2}
=====================

Ethics Statement
----------------

Experiments were conducted in accordance with the Helsinki Declaration of 1975 (revised 1983) and the guidelines of the Salzburg State Ethics Research Committee (AZ2 09-11-E1/823-2006), being no clinical drug trial or epidemiological investigation. In accordance with the Upper Austrian Ethics Committee, upon hospital admission, patients signed an informed consent document concerning the surgical intervention, and agreed to the use of the surgically removed tumor tissue for research purposes. Furthermore, the study did not extend to examination of individual case records. Patient anonymity was ensured at all times. Cancer tissues were derived from surgery. Pituitary glands were obtained post mortem from patients with no signs of brain tumors who died due to either cardiorespiratory failure or brain hemorrhage. Demographics of individual patients are provided in [Supplementary Tables 1--3](#SM1){ref-type="supplementary-material"}.

Patients and Material
---------------------

Formalin-fixed paraffin-embedded (FFPE) tumor tissue of glioma and pituitary adenoma as well as anterior pituitary glands were provided by the Division of Neuropathology, Neuromed Campus, Kepler University Hospital, Linz, Austria.

In total, 55 glioma and 9 pituitary adenoma samples were analyzed for the expression of GAL and GALRs by IHC. Detailed information on tumor subtypes and WHO grades, including astrocytic tumors (*n* = 37), oligodendroglial tumors (*n* = 15) and mixed neuronal-glial tumors (*n* = 3), and age of the patients is provided in [Table 1](#T1){ref-type="table"} and [Supplementary Tables 2, 3](#SM1){ref-type="supplementary-material"}. Data on 7 anterior pituitary glands used for antibody validation are also included ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). The neuropathology diagnosis was based on the diagnostic criteria outlined in the revised 4th edition of the WHO Classification of tumors of the CNS ([@B44]). Briefly, the mutation status of the *IDH1* and *IDH2* genes was assessed for astroglioma and oligodendroglioma; 1p19q co-deletion was determined for oligodendroglioma using multiplex ligation-dependent probe amplification. Cases with a former diagnosis of oligoastrocytoma were re-evaluated using the above-mentioned molecular diagnostic parameters. Two cases of oligoastrocytoma could not be assigned to astroglioma or oligodendroglioma and are therefore described separately. Their data are not included in the statistics.

###### 

Information on tumor samples (incl. WHO classification and grade, sample size (n), and patient age range), positive-stained samples (%), as well as the range of positive-stained cells in (%) and the range of staining intensity.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Tumor type**                 **WHO grade**   ***n***   **Median age \[age range\] (years)**   **Diffuse GAL staining**   **Focal GAL staining**   **GAL~**1**~-R**   **GAL~**2**~-R**   **GAL~**3**~-R**
  ------------------------------ --------------- --------- -------------------------------------- -------------------------- ------------------------ ------------------ ------------------ ------------------
  Pilocytic astrocytoma          I               5         16\                                    100%\                      60%\                     20%\               0%                 20%\
                                                           \[3--20\]                              0--2                       \<1--18%, 1--3           \<1%, 1                               \<1%, 2--3

  Diffuse astrocytoma            II              7         39\                                    100%\                      57%\                     0%                 0%                 0%
                                                           \[4--76\]                              0--2                       2--40%, 1--3                                                   

  Anaplastic astrocytoma         III             7         33\                                    100%\                      86%\                     43%\               0%                 0%
                                                           \[4--61\]                              0--2                       \<1--65%, 1--2           \<1%, 1                               

  Glioblastoma multiforme        IV              8         62\                                    100%\                      75%\                     38%\               0%                 63%\
                                                           \[21--75\]                             0--2                       \<1--30%, 1--2           \<1--8%, 1--2                         \<1--7%, 1--3

  Gliosarcoma                    IV              6         55\                                    100%\                      50%\                     33%\               0%                 50%\
                                                           \[40--68\]                             0--2                       15--70%, 1--2            \<1--1%, 1                            \<1--2%, 1--2

  Giant cell glioblastoma        IV              4         42\                                    100%\                      100%\                    50%\               0%                 0%
                                                           \[24--76\]                             0--1                       35--80%, 1--2            \<1%, 1--2                            

  Oligodendroglioma              II              9         38\                                    89%\                       78%\                     22%\               0%                 11%\
                                                           \[20--76\]                             0--2                       \<1--10%, 1--2           \<1%, 1--2                            \<1%, 1--2

  Anaplastic oligodendroglioma   III             6         36\                                    67%\                       67%\                     17%\               0%                 17%\
                                                           \[31--37\]                             0--2                       \<1--30%, 1--3           1%, 1--2                              \<1%, 1--2

  Ganglioglioma                  I               3         21\                                    67%\                       67%\                     67%\               0%                 67%\
                                                           \[4--21\]                              0--2                       \<1--6%, 2--3            \<1%, 1                               \<1--3%, 1--2

  Pituitary adenoma                              9         57\                                    89%\                       11%\                     0%                 0%                 0%
                                                           \[27--74\]                             0--2                       2%, 2--3                                                       

  Anterior pituitary gland                       7         78\                                    100%\                      100%\                    100%\              0%                 100%\
                                                           \[61--92\]                             1--2                       2--40%, 3                7--15%, 3                             \<1--5%, 2--3
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Immunohistochemistry
--------------------

For IHC analysis, 4 μm FFPE tissue sections were stained as described previously ([@B45]) using the Envision+ System-HRP (DAB) Kit (DAKO, Glostrup, Denmark). After drying for 1 h at 60°C, sections were deparaffinized and rehydrated. Epitope retrieval was performed with EDTA-Tris buffer (1 mM EDTA, 10 mM Tris, pH 9) for 40 min at 95°C. After blocking endogenous peroxidases with "Peroxidase blocking solution" (DAKO), the primary antibody diluted in "Antibody Diluent with Background Reducing Components" (DAKO) was added (40 min, 37°C). The following polyclonal antibodies were used: anti-GAL (Peninsula/Bachem, San Carlos, CA, USA, T-4325, LOT: A14907, rabbit, 1:300), anti-GAL~1~-R (GeneTex Inc., Irvine, CA, USA, GTX108207, LOT: 39771, rabbit, 1:200), anti-GAL~2~-R \[Proteintech Group Inc., Rosemont, IL, USA, customized, LOT: S4510-1, rabbit, 1:400; ([@B45])\] and anti- GAL~3~-R (GeneTex Inc., Irvine, CA, USA, GTX108163, LOT: 39764, rabbit, 1:500). The specificity of the antibodies against human GALRs was recently demonstrated ([@B43], [@B45]). Subsequently, the anti-rabbit secondary antibody "Envision+HRP-labeled polymer" (DAKO) was added for 30 min at RT. For visualization, "Envision+Liquid DAB+Chromogen" (DAKO) was applied (10 min, RT). Mayer\'s hemalum solution (Merck KGaA, Darmstadt, Germany) was used for counterstaining (3--5 min). Slides were immersed in 0.75% HCl in ethanol and rinsed under running tap water (10 min). After dehydration, the slides were mounted with Histokitt (Karl Hecht GmbH & Co KG, Sondheim, Germany). Digital micrographs were taken with a Moticam 5+ camera using Motic Image Plus 2.0 software (Motic, Wetzlar, Germany).

For each round of IHC staining, appropriate control sections were included as quality control. Human skin sections were used as positive controls for GAL \[epidermis, sweat glands ([@B46], [@B47])\] and GAL~3~-R \[blood vessels ([@B48])\]. The cell line SH-SY5Y transfected with human GAL~1~-R or human GAL~2~-R was used as a positive control for GAL~1~-R and GAL~2~-R staining \[[Supplementary Figures 1, 2](#SM1){ref-type="supplementary-material"}; ([@B43], [@B45])\]. Furthermore, as a control, the primary antibody was omitted.

The percentage of stained tumor cells was estimated, excluding adjacent normal appearing tissue, as well as necrotic or hemorrhagic areas. If a section contained \<10 positive-stained cells, the staining was regarded as negative. The staining intensity of tumor cells was rated from negative (0) to strong (3). IHC staining of non-tumor cells, vessels and immune cells such as neutrophils and glioma-associated macrophages/microglia (GAMs) was also evaluated. The IHC analysis was performed by two independent observers.

RT-PCR Analysis
---------------

RNA was isolated from frozen tissue with Tri Reagent (Molecular Research Center Inc., Cincinnati, OH, USA) according to the manufacturer\'s instructions. Two micrograms of human RNA were used to generate cDNA by using maxima reverse transcriptase (Thermo Fisher, Waltham, MA, USA) following the manufacturer\'s protocol. Expression levels were quantified via qPCR using SYBR green SuperMix (BioRad, Hercules, CA, USA). The amplification was performed for 40 cycles (97°C for 15 s, 63°C for 30 s, and 72°C for 10 s) with specific primers for the genes of interest ([Supplementary Table 4](#SM1){ref-type="supplementary-material"}).

Relative expression levels of all genes were calculated as differences between the threshold cycle (Ct) of the gene of interest and Ct of the human housekeeping gene ribosomal protein L27 (RPL27).

Statistical Analysis
--------------------

Cramer-V was used to compare the expression of GAL and GALRs among 55 glioma cases with astrocytic, oligodendroglial, and mixed neuronal-glial tumor subclasses as appropriate. Cramer-V and Fisher\'s exact test were used to compare the expression of GAL and GALRs in glioma of different WHO grades. *P* \< 0.05 was considered significant. All analyses were performed using SPSS 24.0 (SPSS Inc., Chicago, IL., USA).

Results {#s3}
=======

Antibody Validation on Human Anterior Pituitary Glands
------------------------------------------------------

Although the antibodies used in the present studies had been validated on peripheral tissues and overexpressing cell lines, we first validated the IHC protocol for healthy brain tissue, processed the same way as the tumor tissues, and compared the results to mRNA expression data. From seven healthy anterior pituitary glands, half the tissue was fixed in formaldehyde and processed for IHC analysis whereas the other half of the gland was fresh frozen for subsequent mRNA expression analysis.

IHC analysis revealed very strong focal intracellular GAL-immunoreactivity (2--40% of cells) in the pituitary glands. The remaining cells showed diffuse staining for GAL. This diffuse staining might be due to low expression levels and also to intercellular GAL secreted by high- GAL-expressing cells ([Figure 1A](#F1){ref-type="fig"}). The high expression levels of the GAL peptide were also confirmed by RT-PCR analysis ([Figure 2](#F2){ref-type="fig"}).

![Representative images of immunohistochemical staining of **(A)** GAL, **(B)** GAL~1~-R, **(C)** GAL~2~-R, and **(D)** GAL~3~-R in human anterior pituitary gland (case 1). \[scale bar: 100 μm\].](fendo-11-00155-g0001){#F1}

![Relative mRNA expression levels of GAL and GALRs in anterior pituitary glands are shown as ΔCt values relative to the human housekeeping gene hRPL27. The values represent mean ± SD (*n* = 7).](fendo-11-00155-g0002){#F2}

GAL~1~-R was the most prominent receptor in the anterior pituitary gland, with 7--15% positive membrane-associated cellular staining (medium to high staining intensity). GAL~2~-R-immunoreactivity was not detectable in anterior pituitary gland, whereas \<1--5% of cells showed membrane-associated GAL~3~-R-immunoreactivity (medium to high staining intensity; [Figure 1](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}, [Supplementary Table 1](#SM1){ref-type="supplementary-material"}).

The IHC staining results correlate well with mRNA expression, with GAL~1~-R being the most prominent galanin receptor at the mRNA level, followed by GAL~2~-R and GAL~3~-R, which on average showed the same ΔCt values ([Figure 2](#F2){ref-type="fig"}).

### Expression of GAL and GALRs in Pituitary Adenoma

Out of 9 pituitary adenomas, only one, a null-cell tumor (case 7), was positive for GAL, showing medium to strong focal GAL-immunoreactivity in 2% of the tumor cells ([Figure 3A](#F3){ref-type="fig"}). Three pituitary adenomas \[cases 3 (FSH), 5 (null cell), 6 (STH, prolactin)\] had \<10 GAL-positive stained cells and the remaining five were negative for focal GAL staining. Eight pituitary adenomas displayed diffuse GAL-immunoreactivity with low to medium intensity. Case 1 (prolactin) remained completely negative for diffuse and focal GAL staining. None of the GALRs was detectable in pituitary adenoma by IHC staining ([Figures 3B--D](#F3){ref-type="fig"}, [Table 1](#T1){ref-type="table"}, [Supplementary Table 2](#SM1){ref-type="supplementary-material"}).

![Representative images of immunohistochemical staining of in human pituitary adenoma. **(A)** GAL (case 7), **(B)** GAL~1~-R (case 5), **(C)** GAL~2~-R (case 5), and **(D)** GAL~3~-R (case 8). \[scale bar: 100 μm\].](fendo-11-00155-g0003){#F3}

### Expression of GAL and GALRs in Gliomas

Overall, the cellular heterogeneity of glioma subtypes was reflected by a heterogeneous pattern of expression of GAL and GALRs ([Figures 4--6](#F4){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). The majority of gliomas showed focal GAL-immunoreactivity (71% of cases) and regions with diffuse GAL-staining (93% of cases). The proportion of GAL-positive stained cells ranged from \<1 to 80%.

![Representative images of immunohistochemical staining of low-grade astrocytic tumors with **(A--C)** pilocytic astrocytoma (WHO grade I; case 1), **(D--F)** diffuse astrocytoma (WHO grade II; case 8), and **(G--I)** anaplastic astrocytoma (WHO grade III; case 12). GAL immunoreactivity is shown in **(A,D,G)**; GAL~1~-R immunoreactivity in **(B,E,H)**, and GAL~3~-R immunoreactivity in **(C,F,I)**. Arrow heads indicate positive-stained glial cells. \[scale bar: 100 μm\].](fendo-11-00155-g0004){#F4}

The most prominent receptor expressed in glioma was GAL~1~-R (29% of cases), followed by GAL~3~-R (24% of cases). GAL~2~-R was not detectable by IHC in glioma. The proportion of GAL~1~-R-stained cells as well as the proportion of GAL~3~-R-stained cells in the tissue sections was very low (mainly \<1% of tumor cells).

Statistical testing revealed significant correlations between astrocytic, oligodendroglial and mixed neuronal-glial tumors in diffuse GAL staining (*p* = 0.009; Cramer-V). For focal GAL (*p* = 0.963; Cramer-V) as well as GAL~1~-R (*p* = 0.264; Cramer-V) and GAL~3~-R (*p* = 0.137; Cramer-V), no significant correlations between astrocytic, oligodendroglial, and mixed neuronal-glial tumors were observed.

Furthermore, correlations between GAL and GALR expression and different WHO grades I--IV were tested. The only significant correlation was found for GAL~3~-R and WHO grades (*p* = 0.015; Cramer-V): 13 of 55 samples were positive for GAL~3~-R, with 23% of GAL~3~-R positive samples being WHO grade I, 8% WHO grade II, 8% WHO grade III (39% WHO I--III) and 61% WHO grade IV, indicating that the significant correlation is between GAL~3~-R and WHO IV. Further testing of GAL~3~-R against WHO grade IV and non-WHO grade IV confirmed this presumption (*p* = 0.018; Fisher\'s exact test).

### Expression of GAL and GALRs in Astrocytic Tumors

GAL-immunoreactivity showed substantial differences between and within different subtypes of 37 astrocytic tumors (WHO grade I--IV). In 70% of all subtypes, cases of focal GAL-immunoreactivity were observed, although the percentage of GAL-positive cells varied. Furthermore, in all astrocytic tumors, areas with diffuse GAL-staining were noticed ([Figures 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}, [Table 1](#T1){ref-type="table"}, [Supplementary Table 3](#SM1){ref-type="supplementary-material"}). A small proportion of astrocytic tumors revealed expression of GAL~1~-R and GAL~3~-R, but only at low levels and in a small subset of tumor cells. Interestingly, GAL~2~-R-immunoreactivity was not detectable in astrocytic tumors.

![Representative images of immunohistochemical staining of high-grade astrocytic tumors with **(A--C)** glioblastoma multiforme (WHO grade IV; case 18, 17, 20), **(D--F)** gliosarcoma (WHO grade IV; case 27, 25, 27), and **(G--I)** giant cell glioblastoma (WHO grade IV; case 31, 30, 31). GAL immunoreactivity is shown in **(A,D,G)**; GAL~1~-R immunoreactivity in **(B,E,H)**, and GAL~3~-R immunoreactivity in **(C,F,I)**. Arrow heads indicate positive-stained cells whereas the arrows point out GAL~3~-R-positive blood vessels. \[scale bar: 100 μm\].](fendo-11-00155-g0005){#F5}

Sixty percent of pilocytic astrocytomas (WHO grade I) displayed focal GAL-immunoreactivity (\<1--18% GAL-positive tumor cells; [Figure 4A](#F4){ref-type="fig"}, [Table 1](#T1){ref-type="table"}, [Supplementary Table 3](#SM1){ref-type="supplementary-material"}). In 57% of diffuse astrocytomas (WHO grade II), focal GAL-immunoreactivity (2--40% of tumor cells) was detected ([Figure 4D](#F4){ref-type="fig"}). Also, 86% of anaplastic astrocytomas (WHO grade III) contained focal GAL-immunoreactivity (\<1--65% of tumor cells; [Figure 4G](#F4){ref-type="fig"}). In glioblastoma multiforme (WHO grade IV), GAL-positive cell staining was observed in 75% of cases (\<1--30% of tumor cells, [Figure 5A](#F5){ref-type="fig"}). In gliosarcoma (WHO grade IV), only half of the samples displayed focal GAL-immunoreactivity (15--70% of tumor cells, [Figure 5D](#F5){ref-type="fig"}), whereas all giant cell glioblastomas (WHO grade IV) revealed focal GAL-immunoreactivity (35--80% of tumor cells; [Figure 5G](#F5){ref-type="fig"}).

Only one out of 5 pilocytic astrocytoma (WHO grade I) showed GAL~1~-R-immunoreactivity in some tumor cells (\<1% of tumor cells), with low staining intensity ([Figure 4B](#F4){ref-type="fig"}). GAL~1~-R-immunoreactivity was not detectable in diffuse astrocytoma (WHO grade II; [Figure 4E](#F4){ref-type="fig"}). About 43% of anaplastic astrocytomas (WHO grade III) revealed some weakly stained GAL~1~-R-positive cells (\<1% of tumor cells; [Figure 4H](#F4){ref-type="fig"}). In 38% of glioblastoma multiforme (WHO grade IV), GAL~1~-R-immunoreactivity was detected (\<1--8% of tumor cells; [Figure 5B](#F5){ref-type="fig"}). One third of gliosarcoma (WHO grade IV) and half of giant cell glioblastoma (WHO grade IV) samples were GAL~1~-R-positive (≤1% of tumor cells; [Figures 5E,H](#F5){ref-type="fig"}).

A single pilocytic astrocytoma (WHO grade I) showed substantial GAL~3~-R expression in some tumor cells (\<1% of tumor cells; [Figure 4C](#F4){ref-type="fig"}). Tumor cell-associated GAL~3~-R-immunoreactivity was not detectable in diffuse astrocytoma (WHO grade II), anaplastic astrocytoma (WHO grade III) and giant cell glioblastoma (WHO grade IV; [Figures 4F,I](#F4){ref-type="fig"}, [5I](#F5){ref-type="fig"}). In contrast, 63% of glioblastoma multiforme samples (WHO grade IV) and 50% of gliosarcomas (WHO grade IV) showed sparse GAL~3~-R-immunoreactivity (\<1--7% of tumor cells; [Figures 5C,F](#F5){ref-type="fig"}).

### Expression of GAL and GALRs in Oligodendroglial Tumors

IHC analysis of 15 human oligodendroglial tumors (WHO grades II and III) revealed focal and diffuse GAL-immunoreactivity in the majority of cases. ([Figure 6](#F6){ref-type="fig"}, [Table 1](#T1){ref-type="table"}, [Supplementary Table 3](#SM1){ref-type="supplementary-material"}). Receptor expression was generally low and found only in a subset of tumor cells. Tumor cell-associated GAL~2~-R-immunoreactivity was not detectable in oligodendroglial tumors.

![Representative images of immunohistochemical stainings of oligodendroglial tumors with **(A--C)** oligodendroglioma (WHO grade II; case 37, 52, 52) and **(D--F)** anaplastic oligodendroglioma (WHO grade III; case 44, 44, 57). GAL immunoreactivity is shown in **(A,D)**; GAL~1~-R immunoreactivity in **(B,E)**, and GAL~3~-R immunoreactivity in **(C,F)**. Arrow heads indicate positive-stained cells. \[scale bar: 100 μm\].](fendo-11-00155-g0006){#F6}

In more detail, 78% of oligodendrogliomas (WHO grade II) showed focal GAL-immunoreactivity (\<1--10% of tumor cells) and 89% contained areas of diffuse GAL staining ([Figure 6A](#F6){ref-type="fig"}). Sixty percent of anaplastic oligodendrogliomas (WHO grade III) showed focal (\<1--30% of tumor cells) and diffuse GAL-staining ([Figure 6D](#F6){ref-type="fig"}).

GAL~1~-R-immunoreactivity was detectable in 22% of oligodendrogliomas (WHO grade II; \<1% of tumor cells; [Figure 6B](#F6){ref-type="fig"}). Anaplastic oligodendroglioma (WHO grade III) revealed sparse tumor cell-associated GAL~1~-R-immunoreactivity in 17% of samples (\<1% of tumor cells; [Figure 6E](#F6){ref-type="fig"}).

Tumor cell-associated GAL~3~-R-immunoreactivity was detectable in 11% of oligodendrogliomas (WHO grade II; \<1% of tumor cells; [Figure 6C](#F6){ref-type="fig"}). Sparse GAL~3~-R-immunoreactivity was detected in 17% of anaplastic oligodendrogliomas (WHO grade III; \<1% of tumor cells; [Figure 6F](#F6){ref-type="fig"}).

### Expression of GAL and GALRs in Mixed Neuronal-Glial Tumors

IHC analysis of three gangliogliomas (WHO grade I; [Figure 7](#F7){ref-type="fig"}, [Table 1](#T1){ref-type="table"}, [Supplementary Table 3](#SM1){ref-type="supplementary-material"}) revealed focal (\<1 and 6% of tumor cells) as well as diffuse GAL staining ([Figure 7A](#F7){ref-type="fig"}) in two of the three cases. Interestingly one case was completely negative for focal and diffuse GAL staining.

![Representative images of immunohistochemical stainings of ganglioglioma (WHO grade I), a mixed neuronal-glial tumor, which show **(A)** GAL immunoreactivity (case 34), **(B)** GAL~1~-R immunoreactivity (case 36), and **(C)** GAL~3~-R immunoreactivity (case 34). Arrow heads indicate positive-stained cells whereas the arrow points out a GAL~3~-R positive GAM. \[scale bar: 100 μm\].](fendo-11-00155-g0007){#F7}

GAL~1~-R-immunoreactivity was detectable in 67% of gangliogliomas (WHO grade I; ≤ 1% of tumor cells ([Figure 7B](#F7){ref-type="fig"}).

Tumor cell-associated GAL~3~-R-immunoreactivity was detectable in 67% of gangliogliomas (WHO grade I; \<1--3% of tumor cells; [Figure 7C](#F7){ref-type="fig"}).

### Expression of GAL and GALRs in Oligoastrocytic Tumors

IHC analysis of one oligoastrocytoma (OA, NOS; WHO grade II) and one anaplastic oligoastrocytoma (OAA, NOS; WHO grade III; [Supplementary Table 3](#SM1){ref-type="supplementary-material"}) revealed focal (20 and 90% of tumor cells) as well as diffuse GAL staining.

GAL~1~-R-immunoreactivity was detectable in both cases (WHO grade II and III; \<1% of tumor cells).

Tumor cell-associated GAL~2~-R and GAL~3~-R-immunoreactivity was not detectable.

### Expression of GAL and GALRs in Tumor-Infiltrating Immune Cells

GAL and GALRs were also detected in infiltrating immune cells such a neutrophils and GAMs ([Supplementary Tables 2, 3](#SM1){ref-type="supplementary-material"}). GAL-immunoreactivity was sparse in neutrophilic granulocytes in glioma (5% of 57 cases) and was only observed in subpopulations ([Figure 8](#F8){ref-type="fig"}). In 18% of glioma samples, GAMs were GAL positive ([Figure 9](#F9){ref-type="fig"}). GAL-immunoreactivity was absent in tumor-associated immune cells in pituitary adenoma.

![Representative images of immunohistochemical staining of neutrophil granulocytes stained positive for **(A)** GAL in a gliosarcoma (WHO grade IV; case 29), negative for **(B)** GAL~1~-R in a gliosarcoma (WHO grade IV; case 29) and positive for **(C)** GAL~2~-R in an anaplastic astrocytoma (WHO grade III; case 15) and **(D)** GAL~3~-R in a pilocytic astrocytoma (WHO grade I; case 5). Arrow heads indicate positive-stained neutrophil granulocytes, the arrow indicates a negative neutrophil granulocyte. \[scale bar: 100 μm\].](fendo-11-00155-g0008){#F8}

![Representative images of immunohistochemical staining of GAMs stained positive for **(A)** GAL in an oligodendroglioma (WHO grade II; case 51), **(B)** GAL~1~-R in an anaplastic oligoastrocytoma, NOS III (case 54), **(C)** GAL~2~-R in an anaplastic oligoastrocytoma, NOS III (case 54) and **(D)** GAL~3~-R in a gliosarcoma (WHO grade IV; case 25). Arrow heads indicate positive-stained GAMs and arrows indicate hemosiderophages, which contain brown granules due to hemosiderin. \[scale bar: 100 μm\].](fendo-11-00155-g0009){#F9}

GAL~1~-R-immunoreactivity in GAMs was observed in 16% of glioma samples but was absent in neutrophils. Although GAL~2~-R-immunoreacitivity was undetectable in tumor cells of glioma and pituitary adenoma, 27% of glioma samples, particularly astrocytoma (WHO grade I-III), and 44% of pituitary adenomas revealed a small proportion of GAL~2~-R-positive neutrophilic granulocytes ([Figure 8C](#F8){ref-type="fig"}). GAL~2~-R-positive GAMs were observed in one glioblastoma multiforme (WHO grade IV), one ganglioglioma (WHO grade I) and one anaplastic oligoastrocytoma (OAA, NOS; WHO grade III; [Figure 9C](#F9){ref-type="fig"}).

GAL~3~-R was much more abundant in tumor-associated GAMs. In 35% of glioma samples, particularly high-grade glioma (WHO grade IV), GAL~3~-R-positive stained GAMs were identified ([Figures 9D](#F9){ref-type="fig"}, [10](#F10){ref-type="fig"}). Forty nine percent of glioma samples and two pituitary adenomas revealed GAL~3~-R neutrophilic granulocytes ([Figure 8D](#F8){ref-type="fig"}). GALR-positive GAMs were mainly localized near blood vessels or areas with necrotic tissue ([Figure 10](#F10){ref-type="fig"}). GALR-positive neutrophilic granulocytes were mostly observed in hemorrhagic areas.

![Immunohistochemical staining for GAL~3~-R of a gliosarcoma (WHO grade IV; case 25), showing positive GAMs at the junction of tumor tissue and necrotic tissue in **(A)** 4 × and **(B)** 40 × magnification. \[scale bar: 100 μm\].](fendo-11-00155-g0010){#F10}

In addition to the presence of GAL~3~-R in immune cells, endothelial cells of blood vessels in glioma and pituitary adenoma showed frequent GAL~3~-R-immunoreactivity ([Figure 5I](#F5){ref-type="fig"}, [Supplementary Tables 2, 3](#SM1){ref-type="supplementary-material"}). The other two receptors were not detected around blood vessels.

Discussion {#s4}
==========

In this study, we show for the first time the cellular distribution of GALR proteins in human glioma, pituitary adenoma, and anterior pituitary gland.

Our findings correlate with our previous study, where GAL staining in glial cell bodies was found in 18 out of 20 (90%) human brain tumors, including glioblastoma multiforme (WHO grade IV), meningioma (WHO grade I-II), and gliosarcoma (WHO grade IV) ([@B21]). Presence of GALRs indicated by GAL binding occurred in 6 out of 15 gliomas (40%). In the present study, in 12 out of 18 (67%) gliomas (WHO grade IV), GALRs were detectable by IHC staining. The frequency of GALR-immunoreactivity in tumor cells was usually below 10% and the intensity of IHC staining was mainly low to medium, indicating low expression levels of the GALRs. Such low amounts of GALRs might be undetectable by GAL-binding studies. Due to the use of photoemulsions in binding studies using autoradiography, identification of the underlying cell type is not possible and therefore allocation of the binding to tumor cells, stroma or tumor-associated immune cells is not possible. Thus, we provide here the first evidence of GALR expression in tumor-infiltrating immune cells.

Previous RT-PCR analysis of glioblastoma multiforme (WHO grade IV) revealed that GAL~1~-R is the most prominent receptor, followed by GAL~3~-R and GAL~2~-R ([@B21]). This is in accordance with our study, which revealed GAL~1~-R and GAL~3~-R but not GAL~2~-R immunoreactivity. Low levels of the GALRs might be detectable by RT-PCR analysis but not IHC. This is also evident from our data in pituitary glands, where we detected all three GALRs by RT-PCR but only GAL~1~-R and GAL~3~-R by IHC staining.

Anti-proliferative effects of GAL and GAL~1~-R have been reported for HNSCC ([@B35], [@B36], [@B40], [@B49]). As we observed only minor amounts of GALR-positive tumor cell populations in glioma, downregulation of these receptors may be a survival mechanism of glioma cells to ensure proliferation. In accordance with this hypothesis, GAL suppressed proliferation of human U251 and T98G glioma cells via GAL~1~-R signaling ([@B49]).

Several studies reported GAL-like immunoreactivity in pituitary adenoma ([@B11]--[@B16]). The percentage of GAL-positive cases was dependent on the type of pituitary adenoma. Mainly ACTH-secreting pituitary adenomas were GAL-positive, whereas growth hormone- and prolactin-secreting as well as non-functioning pituitary adenomas showed lower frequencies of GAL-immunoreactivity. In ACTH-secreting adenoma, GAL seems to serve as a biomarker, with GAL levels being inversely correlated with tumor volume. Additionally, GAL-positive corticotroph adenomas were associated with a higher cure rate in patients ([@B15]), suggesting clinical relevance for GAL in this brain tumor type. In our study, 8 of 9 cases of pituitary adenoma had at least some areas with diffuse GAL-immunoreactivity. Our data on the expression of GAL in pituitary adenoma ([Supplementary Table 2](#SM1){ref-type="supplementary-material"}) correlate with previous published data, where 77% of patients with Cushing\'s disease (ACTH-secreting), 25% of patients with acromegaly (growth hormone-secreting), 13% of prolactinomas and 34% of non-functioning tumors expressed GAL ([Supplementary Table 5](#SM1){ref-type="supplementary-material"}).

Corresponding to observations in glioma samples, receptor downregulation might also be a possible mechanism in pituitary adenoma to escape anti-proliferative effects of GAL. While all pituitary gland samples expressed GAL~1~-R and GAL~3~-R, GALR expression was absent in pituitary adenoma. Furthermore, it also seemed that the tumor itself reduced GAL expression, as only 11% of pituitary adenoma showed focal GAL staining, in contrast to 100% of healthy pituitary glands. However, it cannot be ruled out that the observations in pituitary glands and pituitary adenoma are also age-related effects, as the median age of the groups was different.

In general, we observed focal as well as diffuse GAL-like immunoreactivity in human brain tumors. Diffuse GAL staining is representative of secreted GAL peptide being present extracellularly. However, it cannot be determined whether the secreted GAL originates either from the cells in the near vicinity showing focal GAL staining or from other brain regions. Additionally, it is unclear whether the secreted GAL originates from the tumor itself or from adjacent healthy tissue, for example, the pituitary which was shown to exhibit high GAL mRNA levels as well as medium to strong diffuse and focal GAL staining.

The expression of the galanin system analyzed by RT-PCR revealed case-dependent expression patterns of GAL and GALR mRNA ([@B34]). As already discussed above, RT-PCR analysis is more sensitive than IHC and this could partially explain why GALRs were not detectable in tumor cells of our pituitary adenomas by IHC analysis. As RNA is isolated from whole tumor extracts, expression of the receptors in non-tumor cells will also be detected. The level of GALRs expressing immune-infiltrating cells might at least partially account for the case differences in GALR mRNA expression levels in pituitary adenoma ([@B34]). Furthermore, GAL-immunoreactivity was much lower in pituitary adenoma as in the anterior pituitary gland. This is in accordance with GAL mRNA expression data, which showed lower GAL expression levels in 10 out of 13 pituitary adenomas ([@B34]).

The expression of GAL~3~-R in small blood vessels is in agreement with the expression of GAL~3~-R in the skin vasculature ([@B48]).

GAMs are key drivers of the local immunosuppressive microenvironment that promotes tumor progression and tumor resistance to immunomodulating therapeutics. Together with other myeloid cells, such as dendritic cells and neutrophils, GAMs actively shape glioma development and the glioma microenvironment, modulate the anti-tumoral immune response, and support angiogenesis, tumor cell invasion and proliferation ([@B50]). Therefore, it could also be possible that GAL is secreted by the tumor cells showing focal GAL staining to boost tumor-supporting properties of the GAMs.

GAL and GALR mRNA expression has already been reported for immune cells isolated from peripheral blood. Macrophages express and secrete substantial amounts of galanin ([@B7]). However, GAMs showed no detectable GAL-immunoreactivity. In contrast, the majority of GAMs were GAL~3~-R positive. This high proportion of GAL~3~-R-immunoreactivity in GAMs is in contrast to the expression of GALRs in peripheral macrophages. A xanthelasma, also referred to as xanthoma, is a cluster of foam cells in the connective tissue of the skin. The foam cells are formed by macrophages accumulating lipids by phagocytosis ([@B51]). We reported membrane-associated GAL~1~-R as well as GAL~2~-R staining on some macrophages in the xanthelasma deposits ([@B7]). To our knowledge, there are no other studies available on the expression of GALRs in tumor-associated macrophages and therefore it is not known if the expression of GALRs is restricted to GAMs or if this is also the case in tumor-associated macrophages of other tumor entities. In addition, we are not aware of any study reporting the expression of the GAL system, especially GAL~3~-R, in tumor-associated neutrophilic granulocytes.

Interestingly, in our previous studies we observed that GAL can have pro- and anti-inflammatory properties on macrophage function depending on their differentiation and polarization status ([@B7]). Therefore, it could be possible that GAL also induces tumor-suppressing functions in GAL~3~-R positive GAMs. Regarding immunity and inflammation, we reported recently that GAL~3~-R signaling has both pro- and anti-inflammatory properties ([@B48], [@B52]).

Currently, possible treatment strategies targeting GALR subtypes are still hampered by the lack of single-subtype specific agonists or antagonists \[for review see ([@B6])\]. Most available selective ligands are peptidergic compounds, which makes their clinical application problematic due to peptide degradation. Furthermore, a GAL~3~-R-specific non-peptidergic antagonist is available, but we showed non-GALR-mediated toxicity of this compound ([@B53]). Therefore, there is a need to develop novel selective, stable and non-peptidergic GALR ligands.

In conclusion, our data indicate that GALR signaling could influence the behavior of tumor cell-associated immune cells. Future studies should focus on the characterization of the immune cell subtypes expressing GALRs in glioma, for example by using markers to differentiate GAMs into resident microglia and bone marrow-derived macrophages. Based on the size and shape of the cells and their nuclei, GALR-positive GAMs resemble the bone marrow-derived macrophage type. Recently it has been shown that GAL is able to influence immune cell behavior by modulating cytokine expression and release, as demonstrated in human neutrophils, natural killer cells, monocytes and macrophages ([@B7], [@B48], [@B54], [@B55]). Furthermore, galanin down-regulates microglial tumor necrosis factor-alpha production and induces microglial migration ([@B56], [@B57]). Thus, strategies targeting tumor-supportive myeloid cells represent an encouraging novel therapeutic approach and could also be considered for the GAL system.
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